The Philippine Food and Drug Administration, through the Center for Device Regulation, Radiation Health, and Research (FDA-CDRRHR), has released a proposed Circular introducing a comprehensive risk-based framework for post-approval variations of general medical devices (GMD), in vitro diagnostic medical devices (IVDMD), medical device software (MDSW), and health-related devices (HRD) including water purification devices/systems and equipment/devices used in the treatment of sharps, pathological, and infectious wastes.
Medical and health-related devices vary widely in classification, risk, and technology, creating the need for a standardized approach to product variations. To address gaps in the current regulations, the proposed Circular establishes comprehensive guidance on variation applications and aligns with the Global Harmonization Working Party principles on change management while remaining consistent with national requirements.
Introduction of a Risk-Based Variation Classification
The proposed Circular introduces a risk-based framework that classifies post-approval changes for GMD, IVDMD, and HRD into Major Variation and Minor Variation, providing a more structured approach to variation applications than the current framework.
- Major Variation – post-approval changes to a registered MD or HRD that significantly affect safety, quality, efficacy, or intended use.
- Minor Variation – post-approval changes to a registered MD or HRD that are low risk and have no to low impact on safety, efficacy, quality, or intended use.
The Circular also provides clearer guidance on which changes may be processed as variations and which require a new product registration. Examples of changes requiring a new product registration include change in intended use or indication, change in critical raw material, additional manufacturing site, change in sterilization method, among others.
Dedicated Variation Framework for MDSW
One of the most notable additions is the introduction of a dedicated variation framework for MDSW. Under the current framework, software variations are generally managed through the same process as other MDs without a separate software-specific pathway. The proposed Circular establishes dedicated categories for MDSW variations, including:
- Major Variation
- Minor Variation Prior Approval – changes that require FDA-CDRRHR approval prior to its implementation.
- Minor Variation Notification ("Do and Tell") – changes that can be implemented immediately, followed by a report to FDA-CDRRHR within a month of its implementation. These include software changes that:
- Correct inadvertent software errors without introducing new functions or affecting safety/performance, limited to the originally approved specifications.
- Incorporate interfacing with non-medical peripherals (e.g., printers).
- Modify the user interface appearance, without affecting diagnostic or therapeutic functions.
- Changes for all Class A MDSW.
Single Variation Application for Multiple Product Authorizations
The proposed Circular allows a single variation application for multiple valid MD authorizations if the proposed change is identical across all authorizations, held by the same Marketing Authorization Holder (MAH), distributor/importer, or local manufacturer, and does not require product-specific technical assessment. Supporting documents must also apply uniformly to all authorizations.
Submission Procedures and Processing of Variation Application
The proposed Circular introduces a prescribed variation application form and requires applications to be submitted through the designated channels outlined in the draft. The remaining process generally follows current practice, including: scheduled email submission based on the first letter of the MAH's company name, issuance of a Document Tracking Number (DTN), and payment of the applicable fees.
The submission limit is increased from two (2) to five (5) variation applications per company per designated submission day.
For HRD, all variation applications must be submitted on Fridays, regardless of the first letter of the MAH's company name.
Timeline, Fees, and Charges
The draft provides that the processing timeline for variation applications shall continue to follow the latest FDA-CDRRHR Citizen's Charter (2025). Fees shall be based on the prevailing FDA fee schedule and the number of authorizations to be amended. Multiple changes arising from a single regulatory cause shall be treated as one payable variation per authorization, while independent changes shall be subject to separate fees, as determined by the FDA.
Expanded Responsibilities of MAHs and Retailers
The proposed Circular places greater emphasis on post-market responsibilities by requiring MAHs to classify proposed changes appropriately, maintain distribution records for traceability, notify downstream distributors and retailers of approved variations, and monitor any adverse events associated with implemented changes. Retailers would likewise be required to ensure products have valid FDA authorizations, maintain purchase and sales records for traceability, and stop selling products with disapproved variation applications.
The draft also establishes the grounds for non-compliance and the corresponding regulatory and enforcement actions for violations of its provisions.
Call-To-Action
With 26+ years of experience supporting medical device and healthcare companies across Asia Pacific, Qualtech provides Regulatory Affairs, Product Registration and Authorized Representative (AR) services tailored to the Philippine market. Supported by our in-house Philippine team in Makati office, we help medical companies navigate registration requirements, regulatory communications and ongoing compliance obligations to support smoother market entry and long-term market presence.
Contact us to learn more about our market entry support solutions in the Philippines!